GB0403509D0 - Galanin receptors and brain injury - Google Patents

Galanin receptors and brain injury

Info

Publication number
GB0403509D0
GB0403509D0 GBGB0403509.3A GB0403509A GB0403509D0 GB 0403509 D0 GB0403509 D0 GB 0403509D0 GB 0403509 A GB0403509 A GB 0403509A GB 0403509 D0 GB0403509 D0 GB 0403509D0
Authority
GB
United Kingdom
Prior art keywords
brain injury
galanin receptors
galanin
receptors
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0403509.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotargets Ltd
Original Assignee
Neurotargets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd
Priority to GBGB0403509.3A priority Critical patent/GB0403509D0/en
Publication of GB0403509D0 publication Critical patent/GB0403509D0/en
Priority to CNA2005800051943A priority patent/CN1922205A/zh
Priority to EP05701953A priority patent/EP1723175A1/en
Priority to CA002555550A priority patent/CA2555550A1/en
Priority to AU2005214115A priority patent/AU2005214115B2/en
Priority to JP2006552676A priority patent/JP2008501632A/ja
Priority to US10/589,533 priority patent/US20080020975A1/en
Priority to PCT/GB2005/000188 priority patent/WO2005080427A1/en
Priority to US12/606,439 priority patent/US20100184638A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
GBGB0403509.3A 2004-02-17 2004-02-17 Galanin receptors and brain injury Ceased GB0403509D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0403509.3A GB0403509D0 (en) 2004-02-17 2004-02-17 Galanin receptors and brain injury
CNA2005800051943A CN1922205A (zh) 2004-02-17 2005-01-18 甘丙肽受体与脑部损伤
EP05701953A EP1723175A1 (en) 2004-02-17 2005-01-18 Galanin receptors and brain injury
CA002555550A CA2555550A1 (en) 2004-02-17 2005-01-18 Galanin receptors and brain injury
AU2005214115A AU2005214115B2 (en) 2004-02-17 2005-01-18 Galanin receptors and brain injury
JP2006552676A JP2008501632A (ja) 2004-02-17 2005-01-18 ガラニン受容体および脳障害
US10/589,533 US20080020975A1 (en) 2004-02-17 2005-01-18 Galanin Receptors and Brain Injury
PCT/GB2005/000188 WO2005080427A1 (en) 2004-02-17 2005-01-18 Galanin receptors and brain injury
US12/606,439 US20100184638A1 (en) 2004-02-17 2009-10-27 Galanin Receptors and Brain Injury

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0403509.3A GB0403509D0 (en) 2004-02-17 2004-02-17 Galanin receptors and brain injury

Publications (1)

Publication Number Publication Date
GB0403509D0 true GB0403509D0 (en) 2004-03-24

Family

ID=32039889

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0403509.3A Ceased GB0403509D0 (en) 2004-02-17 2004-02-17 Galanin receptors and brain injury

Country Status (8)

Country Link
US (2) US20080020975A1 (enExample)
EP (1) EP1723175A1 (enExample)
JP (1) JP2008501632A (enExample)
CN (1) CN1922205A (enExample)
AU (1) AU2005214115B2 (enExample)
CA (1) CA2555550A1 (enExample)
GB (1) GB0403509D0 (enExample)
WO (1) WO2005080427A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809619A1 (en) 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
AU2008207287A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
WO2009079078A1 (en) 2007-12-14 2009-06-25 Labogroup S.A.S. Delivering aerosolizable food products
CN108404115A (zh) 2010-10-15 2018-08-17 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
EP2821081A1 (en) * 2013-07-05 2015-01-07 ResuSciTec GmbH Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
KR101514440B1 (ko) * 2013-12-13 2015-04-22 고려대학교 산학협력단 갈라닌 수용체 3형의 리간드로서 스펙신의 용도
US10314911B2 (en) * 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
KR101885238B1 (ko) * 2015-11-30 2018-08-06 주식회사 뉴라클사이언스 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도
CN106880837A (zh) * 2015-12-15 2017-06-23 北京脑重大疾病研究院 一种甘丙肽在制备防止缺血性脑卒的试剂中的应用
ES2707210B2 (es) * 2017-10-02 2020-09-30 Univ Malaga GAL(1-15) y análogos de la misma para uso en la prevención y/o tratamiento de trastornos y efectos relacionados con el alcohol.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216227A1 (en) * 1996-01-24 1997-07-31 Synaptic Pharmaceutical Corporation Dna encoding galanin galr2 receptors and uses thereof
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
EP0918455B1 (en) * 1996-07-24 2003-04-16 Neurotargets Limited Use of galanin to repair nerve damage
WO1998029440A1 (en) * 1996-12-27 1998-07-09 Merck & Co., Inc. Mouse galanin receptor galr2 and nucleotides encoding same
US6337206B1 (en) * 1997-12-18 2002-01-08 Merck & Co., Inc. Nucleic acid encoding mouse galanin receptor (GALR2)
WO2002096934A1 (en) * 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands

Also Published As

Publication number Publication date
US20100184638A1 (en) 2010-07-22
CA2555550A1 (en) 2005-09-01
CN1922205A (zh) 2007-02-28
US20080020975A1 (en) 2008-01-24
AU2005214115A1 (en) 2005-09-01
JP2008501632A (ja) 2008-01-24
WO2005080427A1 (en) 2005-09-01
AU2005214115B2 (en) 2010-08-12
EP1723175A1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
EP1732381A4 (en) DEVICE AND METHOD FOR FEEDING ANIMALS
IL178697A0 (en) Transgenic animals and uses thereof
EP1827490A4 (en) IMPLANTABLE DEVICE
GB0415112D0 (en) Therapeutic device
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
GB2427181B (en) Improved roping device
GB0403509D0 (en) Galanin receptors and brain injury
GB2407471B (en) Animal harness
GB2420820B (en) Improved attachment device
GB2427117B (en) Improved fish stunning device
GB0419240D0 (en) Therapeutic device
GB2426175B (en) Harvesting device
GB0406164D0 (en) Device for stimulating muscle
SG119302A1 (en) Human trace amine associated receptors
GB0500234D0 (en) Animal treat
GB0401806D0 (en) Animal restrawing device
EP1814423A4 (en) HARNESS
GB0420021D0 (en) Horse and rider rug
GB0427882D0 (en) Therapeutic uses for honey
PL115026U1 (en) Adjustable length life-line
AU156687S (en) Halter top
ZA200507441B (en) Energiser
AU157407S (en) Stimulation device
AU156908S (en) Stimulation device
GB0417229D0 (en) Keeping your pets safe

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)